dc.contributor.author | Arizmanoglou, Alexis | |
dc.contributor.author | Brandl, Ulrich | |
dc.contributor.author | Cross, Helen | |
dc.contributor.author | Gil-nagel, Antonio | |
dc.contributor.author | Lagae, Lieven | |
dc.contributor.author | Landmark, Cecilie Johannessen | |
dc.contributor.author | Specchio, Nicola | |
dc.contributor.author | Nabbout, Rima | |
dc.contributor.author | Thiele, Elisabeth | |
dc.contributor.author | Gubbay, Oliver | |
dc.date.accessioned | 2020-02-28T15:35:41Z | |
dc.date.accessioned | 2020-03-28T12:44:44Z | |
dc.date.available | 2020-02-28T15:35:41Z | |
dc.date.available | 2020-03-28T12:44:44Z | |
dc.date.issued | 2020-12-19 | |
dc.identifier.citation | Arizmanoglou, Brandl, Cross, Gil-nagel, Lagae L, Landmark CJL, Specchio, Nabbout R, Thiele, Gubbay. Epilepsy and cannabidiol:a guide to treatment. Epileptic disorders. 2020;22(1):1-14 | en |
dc.identifier.issn | 1294-9361 | |
dc.identifier.issn | 1294-9361 | |
dc.identifier.uri | https://hdl.handle.net/10642/8335 | |
dc.description.abstract | The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy. | en |
dc.description.sponsorship | A. Arzimanoglou receives salary support from the University Hospitals of Lyon (HCL). His work is also partly supported by the European Union grant for the coordination of the EpiCARE European Reference Network. He has a mission of Editor-in-Chief for the ILAE educational journal Epileptic Disorders and of Associate Editor for the European Journal of Paediatric Neurology. He is an investigator on research grants awarded to HCL, France and Sant Joan de Deu Hospital Barcelona from the Caixa Foundation, GW Pharma and UCB; he has received travel expenses or consulting fees from Advicenne Pharma, Amzell, Arvelle, Biomarin, Eisai, GW Pharma, Lündbeck, Sanofi, Shire, Takeda, UCB Pharma, Zogenix. R. Nabbout receives salary from APHP and university Paris Descartes. She reports grants from EU (EJP-RD, Horizons 2020, and FP7), research grants from Shire, Livanova, Eisai and UCB, consulting and lecturer fees from Eisai, Advicenne Pharma, Takeda, Biomarin, Lundbeck, Zogenix, novartis, and GW pharma, outside the submitted work. Antonio Gil-Nagel has received support from Zogenix, Bilal, Stoke Therapeutics, GW, UCB, Arvelle Therapeutics, Sanofi, Marinus Pharma. Nicola Specchio has received grant support and fees for advisory board participation from GW Pharma. J. Helen Cross has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo and Marinius. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her work is supported by the NIHR Biomedical Research Centre at Great Ormond Street Hospital & University College London. U. Brandl, Lieven Lagae, Cecilie Johannessen Landmark, Oliver Gubbay, and EA. Thiele have no disclosures. The workshop was supported by an educational grant from the Fundació Sant Joan de Déu (Barcelona, Spain) and the Association ESEFNP (Lyon, France). | en |
dc.language.iso | en | en |
dc.publisher | Wiley | en |
dc.relation.ispartofseries | Epileptic Disorders;Volume 22, Issue 1, February 2020 | |
dc.rights | This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License | en |
dc.rights.uri | https://creativecommons.org/licenses/by-sa/4.0/ | |
dc.subject | Epilepsy | en |
dc.subject | Cannabis | en |
dc.subject | Cannabidiol | en |
dc.subject | Oil | en |
dc.subject | Guidelines | en |
dc.subject | Dravet syndrome | en |
dc.title | Epilepsy and cannabidiol: a guide to treatment | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2020-02-28T15:35:41Z | |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://doi.org/10.1684/epd.2020.1141 | |
dc.identifier.cristin | 1798543 | |
dc.source.journal | Epileptic disorders | |